Recruiting
Sponsor: Sarcoma Alliance for Research through Collaboration
Collaborators: Stand Up To Cancer, Merck Sharp & Dohme Corp.
Information provided by (Responsible party): Sponsor
ClinicalTrials.gov Identifier: NCT03092323
Disease free survival [Time Frame: 2 Years] [Designated as safety issue: ]
Loco-regional disease-free survival [Time Frame: 5 years] [Designated as safety issue: ]
Distant disease free survival [Time Frame: 5 years] [Designated as safety issue: ]
Overall survival [Time Frame: 5 years] [Designated as safety issue: ]
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [Time Frame: 5 years] [Designated as safety issue: ]
Ages Eligible for Study: N/A-N/A
Genders Eligible for Study: All
Accepts Healthly Volunteers: No
Sarcoma Alliance for Research through Collaboration
Stand Up To Cancer
Merck Sharp & Dohme Corp.
No publications provided
Sarcoma
Pembrolizumab
ClinicalTrials.gov processed this data on February 25, 2021